Browse the evidence

Semaglutide 2.4 mg weekly reduces cardiovascular mortality, myocardial infarction, and stroke in overweight/obese patients without diabetes but with cardiovascular disease.

If you have obesity and existing heart disease, even without diabetes, semaglutide 2.4 mg weekly can significantly reduce your risk of heart attack, stroke, and death. This is a critical benefit beyond weight loss. Discuss this with your doctor to see if you qualify for this treatment.

GLP-1 receptor agonists reduce cardiovascular risk in patients with obesity and established cardiovascular disease, even in the absence of diabetes.

For individuals with obesity and existing heart disease, GLP-1 medications like semaglutide can significantly reduce the risk of major cardiovascular events and promote weight loss, even without diabetes. This makes them a valuable tool for comprehensive heart health management.

Glucagon-like peptide-1 (GLP-1) receptor agonists, specifically tirzepatide, significantly reduce AHI and improve hypoxic burden in patients with moderate-to-severe OSA and obesity, independent of or adjunct to CPAP use.

If you have moderate to severe sleep apnea and obesity, ask your doctor about Tirzepatide. Recent clinical trials show it significantly reduces breathing interruptions during sleep and improves oxygen levels, even for those already using CPAP. It has received FDA approval for this use. Be prepared for mild stomach issues initially, which usually subside.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce major adverse cardiovascular events (MACE) and all-cause mortality in patients with type 2 diabetes, with specific agents like liraglutide and semaglutide demonstrating superior efficacy.

If you have Type 2 Diabetes and are at risk for heart problems, ask your doctor about GLP-1 medications like semaglutide or liraglutide. These drugs not only help control blood sugar but have been proven to significantly lower your risk of heart attack, stroke, and death. Newer oral versions are available if you dislike injections.

SGLT-2 inhibitors (SGLT-2is) reduce major adverse cardiovascular events and renal outcomes in patients with Type 2 Diabetes, with specific agents like empagliflozin and canagliflozin showing significant benefits.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT-2 inhibitors like empagliflozin or canagliflozin. These pills help your body remove excess sugar through urine, which has been shown to significantly protect your heart and kidneys. They are often used alongside metformin.

GLP-1 receptor agonists provide cardiovascular benefits for patients with obesity, even those without diabetes, by reducing the risk of major adverse cardiovascular events.

GLP-1 medications like Semaglutide (2.4 mg weekly) have been shown to reduce the risk of heart attacks, strokes, and cardiovascular death in people with obesity, even if they don't have diabetes. This is a significant benefit beyond weight loss. However, these drugs are expensive and require long-term use.

SGLT2 inhibitors and GLP-1 receptor agonists provide significant cardiovascular and renal protective benefits independent of their blood glucose-lowering effects, making them suitable for treating heart failure and chronic kidney disease in diabetic patients.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors (like Jardiance or Farxiga) or GLP-1 agonists (like Ozempic or Trulicity). These drugs not only help control blood sugar but also protect your heart and kidneys, which is often more important than just lowering the number on the glucose meter.

GLP-1 receptor agonists (liraglutide, semaglutide) mitigate cardiovascular risks and may reduce atherosclerosis through anti-inflammatory mechanisms.

For patients with type 2 diabetes or cardiovascular disease, GLP-1 receptor agonists like liraglutide and semaglutide offer additional benefits beyond weight loss, including reduced cardiovascular risk and potential mitigation of atherosclerosis through anti-inflammatory effects.

Tirzepatide provides cardiovascular protection by reducing major adverse cardiovascular events (MACE) and improving cardiovascular risk scores in patients with type 2 diabetes and obesity.

Tirzepatide not only helps with weight and blood sugar but also lowers your long-term risk of heart attack and stroke. It improves blood pressure and cholesterol, contributing to overall heart health.

GLP-1 receptor agonists (GLP-1RAs) significantly slow chronic kidney disease (CKD) progression and reduce mortality in patients with type 2 diabetes and CKD.

If you have type 2 diabetes and kidney disease, ask your doctor about GLP-1 receptor agonists like semaglutide. These medications not only help with blood sugar and weight but also significantly slow the progression of kidney damage and reduce the risk of heart problems and death. While side effects like nausea and high costs can be barriers, the long-term benefits for kidney and heart health are substantial and supported by major clinical trials.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly improves metabolic parameters associated with biological aging by restoring glycemic control and reducing visceral adiposity.

If you have type 2 diabetes or obesity, Tirzepatide is an FDA-approved option that directly targets the metabolic dysfunction driving biological aging. It works by mimicking hormones that regulate blood sugar and appetite, leading to significant weight loss and improved glycemic control. Discuss with your doctor if this aligns with your health goals.

Targeting obesity with GLP-1-based therapies reduces major adverse cardiovascular events (MACE) in patients with established atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity, even without diabetes.

If you have heart disease and are overweight or obese, even without diabetes, treating your obesity with semaglutide (2.4 mg weekly) can significantly lower your risk of heart attack, stroke, or cardiovascular death by 20%. This treatment addresses the root metabolic driver of your cardiovascular risk.

The proportion of participants discontinuing treatment for any reason was lower with semaglutide (13.5%) compared to liraglutide (27.6%).

Semaglutide may lead to better treatment adherence compared to liraglutide.

The safety profile of orforglipron was consistent with that of the GLP-1 receptor agonist class, with gastrointestinal events being the most common adverse effects.

Practitioners should be aware of the gastrointestinal side effects associated with orforglipron, particularly during dose escalation.

The combination of Semaglutide and VLCD provoked greater improvements in pancreatic beta-cell function than VLCD alone.

Combining Semaglutide with VLCD may enhance pancreatic function in T2D management.

Leptin, GDF-15, and FGF-21 decreased, whereas adiponectin increased after weight loss.

Monitoring these biomarkers can provide insights into the effects of weight loss on metabolic health.

Higher dose levels of GLP-1RAs may have better effects on weight loss.

Consideration of dose levels may optimize weight loss outcomes with GLP-1RAs.

Tirzepatide was associated with a significantly lower risk of all-cause mortality compared with bariatric metabolic surgery (BMS) (HR, 0.311; 95% CI, 0.257-0.375; p < 0.0001).

Tirzepatide may be a safer option for reducing mortality in obese patients compared to surgical interventions.

Tirzepatide reduced the risk of major adverse cardiovascular events (MACEs) (HR, 0.743; 95% CI, 0.673-0.821; p < 0.0001).

Tirzepatide may help reduce cardiovascular risks in obese patients.

Tirzepatide reduced the risk of major adverse kidney events (MAKEs) (HR, 0.375; 95% CI, 0.336-0.419; p < 0.0001).

Tirzepatide may be beneficial for kidney health in obese patients.

Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the patients in the semaglutide group compared to 34.3% in the placebo group.

Semaglutide may be an effective treatment option for improving liver histology in patients with MASH.

In the 15-mg tirzepatide group, 62% of participants achieved resolution of MASH without worsening of fibrosis compared to 10% in the placebo group (difference of 53 percentage points; P<0.001).

Tirzepatide may be an effective treatment option for patients with MASH and moderate to severe fibrosis.

GLP-1 RA use is associated with increased risk of gallbladder or biliary diseases for longer durations (RR, 1.40; 95% CI, 1.26-1.56) compared to shorter durations (RR, 0.79; 95% CI, 0.48-1.31).

Clinicians should monitor patients on GLP-1 RAs for gallbladder issues, especially with prolonged use.

1-year reinitiation was lower for those without type 2 diabetes (36.3%) compared with those with type 2 diabetes (47.3%).

Practitioners should note that patients without type 2 diabetes may have lower rates of reinitiating GLP-1 RA therapy.